Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.36 |
| ▸ | PPARD | Q03181 | 5/20 | 0.36 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 2/20 | 0.30 |
| ▸ | PPARA | Q07869 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10303196 | 0.95 | FFAR1 (0.37) | FFAR1PPARDRARARARBS1PR1 | |
| SCHEMBL10303298 | 0.89 | FFAR1 (0.36) | FFAR1PPARDRARARARBS1PR1 | |
| SCHEMBL10303270 | 0.89 | FFAR1 (0.42) | FFAR1PPARDRARARARBFAAH | |
| SCHEMBL12822589 | 0.88 | FAAH (0.33) | FFAR1PPARDRARARARBS1PR1 | |
| SCHEMBL10303006 | 0.87 | S1PR1 (0.37) | RARARARBS1PR1FAAHCNR2 | |
| SCHEMBL10303233 | 0.87 | RET (0.31) | CNR2CNR1 | |
| SCHEMBL10303155 | 0.85 | FFAR1 (0.34) | FFAR1S1PR1CNR2 | |
| SCHEMBL10303117 | 0.85 | ERN1 (0.36) | FFAR1PPARDS1PR1FAAHCNR2 | |
| SCHEMBL10303284 | 0.84 | CNR2 (0.32) | FFAR1CNR2CNR1L3MBTL1 | |
| SCHEMBL12823268 | 0.84 | FAAH (0.35) | FFAR1PPARDRARARARBS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216489-B2 | Three-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
| WO-2009125668-A1 | TRICYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | チッソ株式会社 (JP) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | FFAR1 681/4885PPARD 3874/4885RARA 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.